P
Peter T. Silberstein
Researcher at Creighton University
Publications - 189
Citations - 1788
Peter T. Silberstein is an academic researcher from Creighton University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 18, co-authored 109 publications receiving 1523 citations. Previous affiliations of Peter T. Silberstein include United States Department of Veterans Affairs & University of Nebraska Medical Center.
Papers
More filters
Journal ArticleDOI
Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy
Thomas E. Witzig,Peter T. Silberstein,Charles L. Loprinzi,Jeff A. Sloan,Paul J. Novotny,James A. Mailliard,Kendrith M. Rowland,Steven R. Alberts,James E. Krook,Ralph Levitt,Roscoe F. Morton +10 more
TL;DR: The results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia and reduced transfusions in this patient population.
Journal ArticleDOI
Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7
Axel Grothey,Daniel A. Nikcevich,Jeff A. Sloan,John W. Kugler,Peter T. Silberstein,Todor Dentchev,Donald B. Wender,Paul J. Novotny,Umesh Chitaley,Steven R. Alberts,Charles L. Loprinzi +10 more
TL;DR: IV Ca/Mg is supported as an effective neuroprotectant against oxaliplatin-induced cumulative sNT in adjuvant colon cancer in a nonrandomized, retrospective study.
Journal ArticleDOI
Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study.
Patricia Mucci-LoRusso,Barry S. Berman,Peter T. Silberstein,Marc L. Citron,Linda R. Bressler,Sharon M. Weinstein,Robert Francis Kaiko,Barbara J. Buckley,Robert F. Reder +8 more
TL;DR: While adverse experiences were similar, controlled‐release oxycodone was associated with less itching and no hallucinations, and provides a rational alternative to controlled‐ release morphine for the management of moderate to severe cancer‐related pain.
Journal ArticleDOI
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Long-Acting Methylphenidate for Cancer-Related Fatigue: North Central Cancer Treatment Group NCCTG-N05C7 Trial
Amanda R. Moraska,Amit J. Sood,Shaker R. Dakhil,Jeff A. Sloan,Debra L. Barton,Pamela J. Atherton,Jason Suh,Patricia C. Griffin,David B. Johnson,Aneela Ali,Peter T. Silberstein,Steven F. Duane,Charles L. Loprinzi +12 more
TL;DR: This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.
Journal ArticleDOI
Epidemiology of Thyroid Cancer: A Review of the National Cancer Database, 2000-2013.
TL;DR: It is suggested that the increasing incidence of thyroid cancer in the United States is due to overdiagnosis and that more aggressive disease is not being removed by early detection.